Delivery Order SPE2DB22D2206-SPE2DB25FGF19

Award Date 3/21/25
Potential Completion Date 4/11/25
Potential Value $178K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $74,890.20, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of January 24, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of REVLIMID 25 MG CAPSULE 21S. The contract has a firm fixed price ceiling value of $37,445.14 and an ultimate completion date of December 12, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm-fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $37,445.14, is a delivery order for the supply of REVLIMID 20 MG CAPSULE 21S. It is a Firm Fixed Price contract with an ultimate completion date of April 2, 2025. The contract is not associated with a set-aside program. Amerisourcebergen Drug Corp is the prime contractor, and there is no mention of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a firm fixed price delivery order for the supply of REVLIMID 10 MG Capsules. The award has a ceiling value of $105,612.88 and an ultimate completion date of May 3, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside...
This federal contract award, valued at $52,896.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is a firm fixed price delivery order for the supply of REVLIMID 25 MG CAPSULE 100S, a pharmaceutical product. The award does not have a set-aside designation. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $52,448.87 firm fixed-price delivery order contract is for the supply of REVLIMID 5 MG CAPSULE 100S, a medication used in the treatment of various medical conditions. The contract has an ultimate completion date of January 17, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract...
This federal contract award, valued at $28,471.12, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product, with a completion date of January 8, 2024. This is a firm fixed price delivery order contract, with no set-aside designation. Amerisourcebergen Drug Corp is an established prime contractor providing a wide range of pharmaceutical...
This federal contract award, valued at $18,722.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of REVLIMID 15 MG CAPSULE 21S, a prescription medication. The contract has an ultimate completion date of March 12, 2025 and was awarded on February 19, 2025. This contract award is associated with a larger Indefinite Delivery...
This federal contract award, valued at $89,155.06, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,567,951,671 units of the medication REVLIMID 25 MG CAPSULE 100S, with a performance period through May 7, 2025. The contract is a firm fixed-price, non-set-aside award. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FGF19
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $178,310.12, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 10 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of April 11, 2025 and was awarded on March 21, 2025. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor and has no listed major subcontractors. The DLA, a defense agency, is the funding agency for this contract, which is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 6/21/25, 9:46 AM